

comprising from about 2% to about 75% by weight of *d-threo*-methylphenidate in admixture with one or more binders, and a coating consisting of an ammonio methacrylate copolymer in an amount sufficient to provide a dose of said *d-threo*-methylphenidate hydrochloride delayed by from about [4] 2 hours to about 7 hours following said ingestion.

*Q14*  
Add new claims 4-13 as follows.

*A.3*  
A method for treating disease amenable to treatment with a phenidate drug in a patient in need of such treatment comprising administering to the patient a dosage form providing once-daily oral administration of the phenidate drug, said dosage form comprising two groups of particles, each containing the drug wherein:

a) said first group of particles comprises from about 2% to about 99% by weight of the phenidate drug and provides a substantially immediate dose of said phenidate drug upon ingestion by a mammal; and  
b) said second group of particles comprises coated particles, said coated particles comprising from about 2% to about 75% by weight of the phenidate drug in admixture with one or more binders, and a coating consisting of an ammonio methacrylate copolymer in an amount sufficient to provide a dose of said phenidate drug delayed by from about 2 hours to about 7 hours following said ingestion.

*45.*  
The method of claim *4* wherein said delay is at least about 3 hours.

*56.*  
The method of claim *4* wherein said delay is at least about 4 hours.

*67.*  
The method of claim 1 wherein said delay is at least about 3 hours.

*78.*  
The method of claim 1 wherein said delay is at least about 4 hours.

*1.*  
The dosage form of claim 2 wherein the temporal separation is at least about 3 hours.

*10.*  
The dosage form of claim 2 wherein the temporal separation is at least about 4 hours.

*11.*  
The dosage form of claim *2* wherein the temporal separation is at least about 3 hours.

*9.*  
The dosage form of claim *2* wherein the temporal separation is at least about 4 hours.

*12.*